📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
Latest filing: 2026-08-20 16:35
690 analysed today
690
Today
133,579
All-time analysed
40,122
Positive
6,284
Negative
79,354
Neutral
7,751
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
23 announcements match the current filters (relevance ≥ 5).
IOLCP Q1 FY27 Earnings Call: PAT Jumps 89.9% YoY to ₹64.5 Cr; FY27 Growth Guided at 15-20%
IOL Chemicals and Pharmaceuticals reported a 37% YoY growth in Q1 FY27 revenue to ₹756 crore, driven by strong API diversification and higher capacity utilization. Operating EBITDA rose 60.7% YoY to ₹111 crore with margins expanding to 14.6% (up 220 bps YoY), while net profit surged 89.9% YoY to ₹64.5 crore. Non-Ibuprofen API revenue grew 67% YoY to account for 43% of pharma sales. For FY27, management guided for 15-20% revenue growth with EBITDA margins in the range of 14-15% and an export contribution of 25-30%.
Confidence: HIGH
What changedSubmission of the Q1 FY27 earnings call transcript detailing product diversification, export growth, and FY27 guidance.
Why it mattersDemonstrates rapid expansion in non-Ibuprofen APIs (Metformin, Paracetamol, Clopidogrel), reducing legacy product concentration and improving operating leverage.
Q1 FY27 Revenue: ₹756 crQ1 FY27 PAT: ₹64.5 crEBITDA Margin: 14.6%FY27 Revenue Growth Guidance: 15% to 20%Export Share: 28.5%
📅 Short termStable to positive sentiment following solid Q1 operating execution and steady margin guidance.
📈 Long termPortfolio diversification into non-ibuprofen APIs and regulatory approvals (like China NMPA for Clopidogrel) enhance structural growth resilience and margin profile.
⚠ Risk flags
- Raw material price volatility in basic chemicals and reliance on imported inputs
- Sustained pricing pressure in competitive bulk generic chemical and API segments
Key Highlights
Revenue from operations grew 37% YoY to ₹756 crore in Q1 FY27 compared to ₹551 crore in Q1 FY26
Net profit surged 89.9% YoY to ₹64.5 crore with PAT margin improving to 8.4% vs 6.1% in Q1 FY26
Non-Ibuprofen pharma revenue increased 67% YoY, contributing 43% of pharma sales vs 36% in Q1 FY26
FY27 guidance targets 15-20% revenue growth and 14-15% EBITDA margins with export share of 25-30%
Paracetamol capacity (10,800 MTPA) utilization stood at ~55%, targeted to reach ~70% by end of FY27
👀 What to Watch
Track the ramp-up in Paracetamol utilization toward the 70% target and the sustainability of EBITDA margins within the guided 14-15% range over upcoming quarters.
89.9% PAT Growth in Q1 FY27; IOLCP Guides 15-20% Revenue Growth and Rs 250 Cr Capex
IOLCP reported a strong Q1 FY27 with revenue growing 37.1% YoY to Rs 756.3 Cr and PAT surging 89.9% to Rs 64.5 Cr. The company is successfully diversifying its portfolio, with non-Ibuprofen APIs now contributing 37% of pharma sales compared to 18% in FY21. Management has provided a positive outlook for FY27, guiding for 15-20% revenue growth and EBITDA margins of 14-15%. To support this, a capex of Rs 200-250 Cr is planned, alongside the acquisition of 101 acres for a new manufacturing site.
Confidence: HIGH
What changedIOLCP has transitioned from an Ibuprofen-heavy player to a diversified API manufacturer with significant capacity in Paracetamol (10,800 MTPA) and Ethyl Acetate (1,20,000 MTPA).
Why it mattersThe diversification reduces product concentration risk and improves margin resilience through backward integration and a higher share of value-added APIs in regulated markets.
Q1 FY27 Revenue Growth (YoY): 37.1%Q1 FY27 PAT Growth (YoY): 89.9%FY27 Capex Guidance: Rs 200-250 CrCapex vs Net Worth: ~12.5%New Land Acquisition: 101 acresEBITDA Margin (Q1 FY27): 14.6%
📅 Short termThe stock is likely to react positively to the significant bottom-line growth and the clear 15-20% revenue growth guidance for the full year.
📈 Long termStructural growth is supported by the shift toward regulated markets (US/Europe) and the expansion into a new 101-acre site, which provides a long-term runway for capacity additions.
⚠ Risk flags
🔬 Flagged for deeper Multibagger analysis — view briefs →
- High dependency on China for chemical raw materials
- Execution risk on new site development
- Product concentration in Ibuprofen and Ethyl Acetate still remains significant
Key Highlights
Q1 FY27 PAT increased by 89.9% YoY to Rs 64.5 Cr, driven by margin expansion.
Revenue from operations grew 37.1% YoY to Rs 756.3 Cr for the quarter.
Non-Ibuprofen API share in the pharmaceutical segment reached 37% in FY26, up from 18% in FY21.
Management guided for a FY27 Capex of Rs 200-250 Cr, representing ~11-14% of current net worth.
Acquired 101 acres of land near Chandigarh-Bathinda Highway for future industrial expansion.
👀 What to Watch
Monitor the execution of the Rs 200-250 Cr capex and the timeline for regulatory approvals for the new 101-acre site. Watch for the company's ability to maintain the 14-15% EBITDA margin guidance amidst volatile raw material costs from China.
89.9% PAT Growth: IOLCP Reports Record ‡756.3 Cr Revenue in Q1 FY27
IOLCP delivered a record-breaking Q1 FY27 with revenue growing 37.1% YoY to ‡756.3 Cr, significantly outpacing its historical quarterly run rate. Net profit (PAT) surged 89.9% YoY to ‡64.5 Cr, driven by a 43% growth in the Pharma segment and a massive 193% jump in Chemical segment EBIT. EBITDA margins expanded to 14.6% from 12.4% YoY, supported by higher capacity utilization and a better product mix. Notably, non-Ibuprofen products now contribute 43% of Pharma revenue, reducing concentration risk.
Confidence: HIGH
What changedIOLCP achieved its highest-ever quarterly revenue and significantly improved its product mix, with non-Ibuprofen APIs now making up nearly half of pharma sales.
Why it mattersThe results demonstrate successful diversification away from Ibuprofen dependence and improved operational leverage, which structurally enhances the company's profitability profile.
Revenue (Q1 FY27): ‡756.3 CrPAT (Q1 FY27): ‡64.5 CrEBITDA Margin: 14.6%Q1 Revenue vs TTM Revenue: 32.6%Paracetamol Utilization: 65%Export Share: 28.5%
📅 Short termThe stock is likely to react positively to the sharp beat in earnings and margin expansion compared to previous quarters.
📈 Long termThe transition toward a diversified API portfolio and increased presence in regulated markets like China and Europe provides a more stable growth trajectory.
⚠ Risk flags
- Raw material price volatility in China
- Geopolitical supply chain disruptions
Key Highlights
Revenue from operations reached a record ‡756.3 Cr, up 37.1% YoY and 22.1% QoQ.
Net Profit (PAT) grew 89.9% YoY to ‡64.5 Cr, accounting for approximately 47% of the total TTM PAT.
Pharma segment revenue grew 43% YoY to ‡469.5 Cr, with EBIT rising 72% YoY.
Paracetamol capacity utilization improved to 65%, meeting the company's previously stated target.
Export contribution increased to 28.5% of total revenue, up from 24.4% in the same quarter last year.
👀 What to Watch
Monitor the sustainability of the 14.6% EBITDA margin and the volume ramp-up in the Chinese market following the recent NMPA approval for Clopidogrel API.
90% PAT Growth: IOLCP Reports Strong Q1 FY27 with ₹756 Cr Revenue
IOLCP reported a robust start to FY27, with consolidated revenue growing 37.1% YoY to ₹756.26 Cr. Net profit surged 89.9% YoY to ₹64.48 Cr, significantly exceeding the quarterly average of the previous year. The growth was primarily driven by the Pharmaceutical segment, which saw a 42.6% YoY revenue increase, while the Chemical segment's profitability (PBIT) nearly tripled to ₹17.32 Cr.
Confidence: HIGH
What changedIOLCP has delivered a significant earnings beat, with quarterly PAT (₹64.48 Cr) representing nearly half of the entire previous year's profit (₹137.48 Cr).
Why it mattersThe results indicate a successful shift toward the higher-margin Pharmaceutical API business and improved operational efficiency in the Chemical segment, reducing the company's historical dependence on low-margin bulk chemicals.
Q1 Revenue vs TTM Revenue: 32.6%Q1 PAT vs TTM PAT: 47.1%Pharmaceutical Segment PBIT Margin: 14.7%Chemical Segment PBIT Margin: 4.7%Cost of Materials as % of Revenue: 67.0%
📅 Short termThe stock is likely to react positively in the short term due to the substantial YoY and QoQ growth in both revenue and profitability.
📈 Long termIf the company continues to scale its 'differentiated API pipeline' (Metformin, Clopidogrel) and increases export share to regulated markets, it could lead to a structural re-rating of the business.
⚠ Risk flags
- High raw material cost concentration (₹506.76 Cr consumed in Q1)
- Product concentration risk in Ibuprofen and Ethyl Acetate
- Dependency on China for chemical raw materials
Key Highlights
Revenue from operations increased 37.1% YoY to ₹756.26 Cr from ₹551.69 Cr.
Net profit for the quarter rose 89.9% YoY to ₹64.48 Cr compared to ₹33.96 Cr in Q1 FY26.
Pharmaceutical segment revenue grew 42.6% YoY to ₹469.49 Cr, now contributing 56% of gross segment revenue.
Chemical segment PBIT improved significantly to ₹17.32 Cr from ₹5.91 Cr in the year-ago period.
Quarterly EPS stood at ₹2.20, which is approximately 47% of the total FY26 EPS of ₹4.69.
👀 What to Watch
Investors should monitor the sustainability of the Pharmaceutical segment's growth and whether the Chemical segment can maintain its improved margins despite raw material volatility. Watch for management commentary on Paracetamol capacity utilization reaching the 65% target.
NMPA China Approves IOLCP's Clopidogrel Bisulfate API on July 14, 2026
IOL Chemicals and Pharmaceuticals (IOLCP) has received regulatory approval from China's NMPA for its Clopidogrel Bisulfate API. This approval allows the company to enter the Chinese pharmaceutical market with this product, complementing its existing European Certificate of Suitability (CEP). This move is part of a broader strategy to diversify its revenue stream, as two products currently account for 72% of total sales. While the immediate financial impact is not disclosed, it supports the company's goal to increase its export revenue share toward 40%.
Confidence: HIGH
What changedIOLCP has gained formal regulatory clearance to market and sell its Clopidogrel Bisulfate API in China, expanding its global footprint.
Why it mattersChina is a massive pharmaceutical market; this approval validates IOLCP's regulatory capabilities and helps diversify its product portfolio away from its heavy reliance on Ibuprofen.
Product Concentration (Top 2): 72%TTM Revenue: Rs 2319 CrExport Revenue Target: 40%Approval Date: 14th July 2026
📅 Short termThe news is likely to be viewed positively by the market as it demonstrates progress in the company's stated strategy of entering regulated markets.
📈 Long termThis is a structural step toward reducing product concentration risk and improving margins by shifting toward higher-value regulated markets like China and Europe.
⚠ Risk flags
- High competition in the Chinese API market
- Raw material price volatility from China
- Execution risk in scaling new product sales
Key Highlights
Approval received from the National Medical Products Administration (NMPA), China, on July 14, 2026.
The approval is for Clopidogrel Bisulfate API, an antiplatelet medication.
IOLCP already holds a valid Certificate of Suitability (CEP) for this product in other markets.
The company is working to reduce its 72% revenue concentration from Ibuprofen and Ethyl Acetate.
👀 What to Watch
Investors should monitor the API segment's revenue growth in upcoming quarters to see how quickly Chinese market access translates into sales volume for Clopidogrel.
IOLCP Reports Strong Q4 FY26: PAT Jumps 68% to ₹53 Cr; Plans ₹1,400 Cr Capex
IOL Chemicals and Pharmaceuticals (IOLCP) delivered a robust performance in Q4 FY26, with revenue growing 17.4% YoY to ₹619 crores and PAT surging 68% to ₹53 crores. The company achieved its highest-ever quarterly revenue, driven by improved capacity utilization in non-Ibuprofen APIs and operational efficiencies. Management has outlined a significant long-term growth plan involving a ₹1,200-1,400 crore capex over the next 4-5 years for a new site, funded entirely via internal accruals. For FY27, the company guides for approximately 15% revenue growth and steady EBITDA margins around 14%.
Key Highlights
Q4 FY26 PAT grew 68% YoY to ₹53 crores, while EBITDA margins expanded by 251 bps to 15.2%
Full-year FY26 revenue reached ₹2,319 crores, up 11.5%, with a total PAT of ₹138 crores
Management announced a mega capex plan of ₹1,200-1,400 crores over 4-5 years for a new 100-acre facility
Capacity utilization for core products like Ibuprofen and Metformin remained high at 85-95%
Non-Ibuprofen segment strengthened with the launch of Minoxidil and expansion of Pantoprazole capacity
👀 What to Watch
Investors should view the margin expansion and diversification into non-Ibuprofen APIs as a positive sign of reduced concentration risk. The massive capex plan indicates long-term growth visibility, though execution and the ability to fund via internal accruals should be monitored.
IOLCP Q4 FY26 PAT Jumps 68.2% YoY to ₹53.2 Cr; EBITDA Margins Expand to 15.2%
IOL Chemicals and Pharmaceuticals (IOLCP) reported a robust Q4 FY26 with revenue growing 17.4% YoY to ₹619.5 Cr and PAT surging 68.2% to ₹53.2 Cr. For the full year FY26, revenue reached ₹2,319.1 Cr with a PAT of ₹137.7 Cr, representing a 36.4% annual growth. The company is successfully diversifying its pharmaceutical mix, with non-Ibuprofen APIs now contributing 37% of segment revenue compared to 18% in FY21. Financial health remains strong with a very low debt-to-equity ratio of 0.08.
Key Highlights
Q4 FY26 EBITDA grew 39.8% YoY to ₹94.3 Cr with margins expanding from 12.7% to 15.2%.
Full-year FY26 revenue from the Pharmaceutical segment rose to ₹1,396.3 Cr from ₹1,212.3 Cr in FY25.
Strategic shift achieved in product mix with non-Ibuprofen APIs now accounting for 37% of pharma sales.
Completed major capacity expansions including Paracetamol (10,800 MTPA) and Ethyl Acetate (1,20,000 MTPA).
Maintained a lean balance sheet with total equity of ₹1,798.4 Cr and a debt-to-equity ratio of 0.08.
👀 What to Watch
Investors should note the significant margin improvement and the successful execution of the diversification strategy which reduces reliance on Ibuprofen. The ramp-up of the new 10,800 MTPA Paracetamol facility and low leverage provide a strong foundation for future growth.
IOLCP Reports Highest-Ever Quarterly Revenue; Q4 PAT Surges 68% YoY to ₹53.2 Cr
IOL Chemicals and Pharmaceuticals achieved its highest-ever quarterly revenue of ₹619.5 crore in Q4 FY26, marking a 17.4% YoY growth. Profitability saw a significant boost with PAT surging 68.2% to ₹53.2 crore and EBITDA margins expanding by 251 bps to 15.2%. The performance was driven by a strong momentum in the non-Ibuprofen pharmaceutical portfolio and improved realizations in the chemicals business. For the full year FY26, the company reported a total revenue of ₹2,319.1 crore and invested ₹164 crore in capacity expansion through internal accruals.
Key Highlights
Q4 FY26 Revenue grew 17.4% YoY to ₹619.5 Cr, the highest quarterly revenue in company history.
EBITDA for the quarter increased 39.8% YoY to ₹94.3 Cr with margins improving to 15.2%.
Net Profit (PAT) for Q4 FY26 surged 68.2% YoY to ₹53.2 Cr compared to ₹31.6 Cr in Q4 FY25.
Pharma segment EBIT rose significantly to ₹62.2 Cr in Q4 FY26 from ₹40.9 Cr in the previous year's quarter.
Annual capex of ₹164 Cr was deployed for capacity expansion in Ethyl Acetate, Acetic Anhydride, and Triacetin.
👀 What to Watch
The significant margin expansion and successful diversification into non-Ibuprofen APIs like Paracetamol and Metformin reduce concentration risk and improve earnings quality. Investors should maintain a positive outlook given the company's ability to fund large expansions through internal accruals while maintaining cost leadership.
IOLCP Expands Portfolio with 6,000 MTPA Triacetin Plant and Pantoprazole Capacity Hike
IOL Chemicals and Pharmaceuticals (IOLCP) has announced the successful installation of a new manufacturing facility for 'Triacetin' with a capacity of 6,000 MTPA at its Barnala plant. The company also increased its Pantoprazole capacity by 15%, raising it from 240 MTPA to 276 MTPA to meet growing market demand. Both projects, involving a total capital expenditure of approximately Rs 22.75 crore, were funded entirely through internal accruals. Additionally, the board has approved the audited financial results for FY26 and scheduled the 39th AGM for September 2, 2026.
Key Highlights
New Triacetin facility established with 6,000 MTPA capacity involving Rs 16.88 crore investment
Pantoprazole capacity enhanced from 240 MTPA to 276 MTPA with an investment of Rs 5.87 crore
Both expansion projects were funded 100% through internal accruals, indicating strong cash flows
39th Annual General Meeting (AGM) fixed for 2nd September 2026 via video conferencing
Audited FY26 financial results approved with an unmodified opinion from statutory auditors
👀 What to Watch
Investors should view the diversification into Triacetin and the capacity hike in Pantoprazole as positive growth drivers that are being funded without adding debt. Monitor the utilization levels of the new Triacetin capacity in upcoming quarters to gauge its impact on the bottom line.
IOLCP Announces FY26 Results and ₹22.75 Cr Capex for Triacetin and Pantoprazole Expansion
IOL Chemicals and Pharmaceuticals Limited (IOLCP) has successfully completed the installation of a new manufacturing facility for 'Triacetin' with a Phase-I capacity of 6,000 MTPA. The company also expanded its Pantoprazole capacity from 240 MTPA to 276 MTPA to address 100% existing capacity utilization and growing demand. The total capital expenditure of ₹22.75 crore for these projects was entirely funded through internal accruals, demonstrating strong cash flow. Additionally, the board approved the audited FY26 financial results and scheduled the 39th AGM for September 2, 2026.
Key Highlights
Launched new product 'Triacetin' with a Phase-I installed capacity of 6,000 MTPA at the Barnala plant.
Increased Pantoprazole capacity by 15%, moving from 240 MTPA to 276 MTPA to meet rising demand.
Total investment of ₹22.75 crore (₹16.88 Cr for Triacetin and ₹5.87 Cr for Pantoprazole) funded via internal accruals.
Audited FY26 financial results approved with an unmodified opinion from statutory auditors.
39th Annual General Meeting (AGM) scheduled for September 2, 2026, via video conferencing.
👀 What to Watch
Investors should view the expansion and diversification into Triacetin as a positive move for long-term revenue growth, especially as it is funded without debt. Monitor the utilization rates of the new capacities in the upcoming quarterly results to gauge market absorption.
IOLCP Promoter Group Entity NCVI Enterprises Acquires 4.04 Lakh Shares for ₹3.01 Crore
NCVI Enterprises Limited, a promoter group entity of IOL Chemicals and Pharmaceuticals Limited, has increased its stake in the company through an open market purchase. The entity acquired 4,04,305 equity shares on March 19, 2026, for a total consideration of approximately ₹3.01 crore. This transaction has resulted in the promoter group's holding rising from 16.44% to 16.58%. Such insider buying is generally perceived as a positive signal, indicating management's confidence in the company's intrinsic value and future growth.
Key Highlights
Promoter group entity NCVI Enterprises Limited purchased 4,04,305 equity shares.
The acquisition was valued at approximately ₹3.01 crore via open market transactions.
The promoter group's stake increased from 16.44% to 16.58% following the purchase.
The transaction was executed on March 19, 2026, and officially disclosed on March 20, 2026.
👀 What to Watch
Investors should take note of this promoter buying as a sign of internal confidence in the company's prospects. It serves as a positive secondary indicator for long-term holders, though it should be weighed alongside broader fundamental performance.
Promoter Group Entity Buys 6.54 Lakh Shares of IOLCP for ₹4.47 Crore
Mayadevi Polycot Limited, a promoter group entity of IOL Chemicals and Pharmaceuticals Limited, has acquired 6,54,123 equity shares through an open market transaction on March 17, 2026. The total acquisition cost was approximately ₹4.47 crore, increasing the entity's stake from 21.54% to 21.76%. This insider purchase is a positive signal, often indicating that the promoter group believes the company's shares are undervalued or has confidence in future growth.
Key Highlights
Acquisition of 6,54,123 equity shares by promoter group entity Mayadevi Polycot Limited
Total transaction value of ₹4,47,17,289 executed via on-market purchase
Promoter entity's stake increased from 21.54% to 21.76% (a 0.22% increase)
Transaction occurred on March 17, 2026, and was disclosed to exchanges on March 18, 2026
👀 What to Watch
Investors should view this promoter buying as a sign of internal confidence in the company's prospects. It may serve as a support level for the stock price, though overall market conditions and sector performance should also be considered.
IOL Chemicals Promoter Group NCVI Enterprises Acquires 7 Lakh Shares via Open Market
NCVI Enterprises Limited, a promoter group entity of IOL Chemicals and Pharmaceuticals Limited (IOLCP), has increased its stake in the company through an open market purchase. On March 16, 2026, the entity acquired 7,00,000 equity shares, representing approximately 0.24% of the company. This transaction raises the promoter group's holding from 15.96% to 16.20%. Such insider buying is generally interpreted as a positive signal of management's confidence in the company's long-term value.
Key Highlights
Promoter group entity NCVI Enterprises Limited acquired 7,00,000 equity shares on March 16, 2026.
The acquisition was executed through an open market transaction.
The promoter group's total shareholding increased from 4,68,50,695 shares (15.96%) to 4,75,50,695 shares (16.20%).
The disclosure was filed under Regulation 7(2) of SEBI (Prohibition of Insider Trading) Regulations.
👀 What to Watch
Promoter buying at market prices often suggests that the leadership believes the stock is undervalued or has strong growth potential. Investors should maintain a positive outlook but continue to monitor the company's quarterly earnings performance.
IOLCP Receives EDQM CEP Certificate for Metformin Hydrochloride Process-II
IOL Chemicals and Pharmaceuticals Limited (IOLCP) has received a Certificate of Suitability (CEP) from the European Directorate for the Quality of Medicines & Health Care (EDQM) for its API product, Metformin Hydrochloride Process-II. This certification, granted on March 5, 2026, is an addition to the company's existing valid CEP for Metformin Hydrochloride. Metformin is a widely used antidiabetic drug for managing blood sugar levels. This regulatory milestone strengthens the company's ability to supply this critical API to the European market and other regions that recognize EDQM standards.
Key Highlights
EDQM granted the CEP for Metformin Hydrochloride Process-II on March 5, 2026
The new certification is in addition to the existing valid CEP already held by the company
Metformin Hydrochloride is a key antidiabetic drug used globally for blood sugar management
The approval enhances IOLCP's regulatory compliance and market access in European territories
👀 What to Watch
Investors should view this as a positive development that reinforces IOLCP's position in the global API market. The additional certification may lead to improved operational flexibility and potential volume growth in the antidiabetic segment.
IOLCP Expands Ethyl Acetate and Acetic Anhydride Capacities via Rs 9.71 Cr Capex
IOL Chemicals and Pharmaceuticals Limited has successfully completed the expansion of its manufacturing facilities for Ethyl Acetate and Acetic Anhydride as of March 2, 2026. The Ethyl Acetate capacity has been increased by 20,000 MTPA to reach 1,20,000 MTPA, while Acetic Anhydride capacity grew by 7,000 MTPA to 32,000 MTPA. The total project cost of Rs 9.71 crore was entirely funded through internal accruals, indicating a healthy balance sheet. This expansion is strategically timed as existing facilities were operating at 90-100% utilization.
Key Highlights
Ethyl Acetate capacity increased from 1,00,000 MTPA to 1,20,000 MTPA (20% increase)
Acetic Anhydride capacity enhanced from 25,000 MTPA to 32,000 MTPA (28% increase)
Total capital expenditure of Rs 9.71 crore funded through internal accruals
Expansion completed on March 2, 2026, to address high utilization rates and market demand
Aims to improve margin realization through optimum operating leverage
👀 What to Watch
Investors should view this as a positive growth signal as the company is expanding capacity in segments where it already has high utilization. The use of internal accruals for capex further strengthens the investment case by avoiding additional debt.
IOLCP Secures EDQM CEP Certification for Clopidogrel Besilate API
IOL Chemicals and Pharmaceuticals Limited (IOLCP) has been granted a Certificate of Suitability (CEP) by the European Directorate for the Quality of Medicines & Health Care (EDQM) for its API product, Clopidogrel Besilate. This certification, issued on February 23, 2026, serves as a significant regulatory milestone for the company's cardiovascular portfolio. IOLCP already maintains a valid CEP for Clopidogrel Bisulphate, and this new addition expands its product range for the European market. The approval is expected to strengthen the company's position as a key supplier of antiplatelet medications globally.
Key Highlights
EDQM issued the CEP for Clopidogrel Besilate on February 23, 2026, following strict quality standards.
The company now holds CEPs for two variants: Clopidogrel Besilate and Clopidogrel Bisulphate.
Clopidogrel is an essential antiplatelet medication used for treating and preventing cardiovascular diseases.
This regulatory approval facilitates easier market access and compliance for IOLCP's API exports to Europe.
👀 What to Watch
This approval strengthens IOLCP's export portfolio and validates its manufacturing quality standards; investors should maintain a positive outlook on the company's API business growth.
IOLCP Q3 FY26 Revenue Up 11% to ₹580 Cr; EBITDA Grows 23% with 10.7% Margin
IOL Chemicals and Pharmaceuticals reported a resilient Q3 FY26 with revenue growing 10.9% YoY to ₹580 crores and EBITDA rising 22.8% to ₹62.6 crores. The company's diversification strategy is yielding results, with non-ibuprofen APIs now contributing ₹128 crores to the pharmaceutical segment. Despite persistent high fuel costs in Punjab, management expects a 1-2% margin improvement in Q4 FY26. The board declared a 50% interim dividend, and the company maintains a positive growth guidance of 10-15% for FY27.
Key Highlights
Revenue from operations increased 10.9% YoY to ₹580 crores, while EBITDA grew 22.8% to ₹62.6 crores.
Non-ibuprofen API portfolio contributed ₹128 crores, reflecting successful diversification away from core ibuprofen products.
Capacity utilization remains robust with Ibuprofen at 90-95% and the Chemicals division at nearly 100%.
Management guided for 10-15% top-line and 15-20% bottom-line growth in FY27, supported by ₹150-200 crore annual capex.
Reported a non-recurring exceptional item of ₹11.2 crores pertaining to new labor law provisions.
👀 What to Watch
Investors should focus on the improving product mix and the ramp-up in paracetamol capacity as key growth drivers. The stock remains a solid play on API diversification and backward integration efficiencies.
IOLCP Declares Rs 1 Interim Dividend; Sets Feb 17 as Record Date for FY 2025-26
IOL Chemicals and Pharmaceuticals Limited (IOLCP) has declared an interim dividend of Rs 1 per equity share, representing 50% of the face value of Rs 2, for the financial year 2025-26. The company has designated February 17, 2026, as the record date to identify eligible shareholders for this payout. Detailed guidelines for Tax Deduction at Source (TDS) have been issued, including a 20% deduction rate for accounts without a valid or linked PAN. Resident individual shareholders are exempt from TDS if their total dividend income from the company does not exceed Rs 10,000 during the fiscal year.
Key Highlights
Interim dividend of Rs 1 per share (50% of face value) declared for FY 2025-26
Record date for dividend entitlement is fixed for February 17, 2026
TDS of 20% applicable for shareholders with invalid or non-Aadhaar linked PAN
Exemption from TDS for resident individuals if total dividend is below Rs 10,000
Deadline for submitting tax exemption forms (15G/15H) is February 17, 2026
👀 What to Watch
Investors should ensure their PAN is correctly linked and bank details are updated in their demat accounts before the record date. Eligible shareholders should submit Form 15G/15H through the Alankit Assignments portal by February 17 to avoid unnecessary tax deductions.
IOLCP Q3 FY26 Results: EBITDA Grows 22.8% YoY to ₹62.6 Cr; Revenue Up 10.9%
IOL Chemicals and Pharmaceuticals Limited (IOLCP) reported a steady Q3 FY26 performance with revenue growing 10.9% YoY to ₹580.4 Cr. EBITDA margins improved to 10.7% from 9.7% YoY, while PBT before exceptional items surged 39.3% to ₹38.8 Cr. The bottom line was slightly impacted by an exceptional charge of ₹11.2 Cr related to new labour code provisions. The company is successfully diversifying its portfolio, with the non-Ibuprofen segment now contributing significantly to growth.
Key Highlights
Revenue from operations increased 10.9% YoY to ₹580.4 Cr in Q3 FY26.
EBITDA grew 22.8% YoY to ₹62.6 Cr with margins expanding by 100 bps to 10.7%.
PBT before exceptional items rose 39.3% YoY to ₹38.8 Cr.
Commenced New Unit 11 for Paracetamol with a significant installed capacity of 10,800 MTPA.
Maintains a very strong financial position with a Debt-to-Equity ratio of 0.07.
👀 What to Watch
Investors should focus on the company's successful transition from an Ibuprofen-heavy player to a diversified API manufacturer. The massive expansion in Paracetamol capacity and low leverage provide a strong foundation for long-term growth.
IOLCP Q3 FY26 Results: PBT Jumps 39.3% YoY to ₹38.8 Cr; Pharma Revenue Up 18%
IOL Chemicals and Pharmaceuticals (IOLCP) reported a robust Q3 FY26 performance with revenue growing 10.9% YoY to ₹580.4 crore. Profit Before Tax (before exceptional items) surged by 39.3% YoY to ₹38.8 crore, supported by a 102 bps expansion in EBITDA margins to 10.7%. The growth was largely driven by the Pharmaceuticals segment, which saw an 18% revenue increase and now accounts for 61% of the total revenue mix, up from 57% last year.
Key Highlights
Revenue from operations increased 10.9% YoY to ₹580.4 Cr in Q3 FY26.
PBT (before exceptional items) grew 39.3% YoY to ₹38.8 Cr with a margin of 6.6%.
Pharmaceuticals segment EBIT rose 32% YoY to ₹34.5 Cr, driven by non-Ibuprofen APIs.
Chemicals segment EBIT grew 37% YoY to ₹6.5 Cr despite flat revenue growth.
9M FY26 EBITDA stands at ₹196.1 Cr, up 24.8% compared to the previous year.
👀 What to Watch
Investors should note the positive shift in product mix towards the higher-margin Pharmaceutical segment and the successful diversification into non-Ibuprofen APIs. The consistent margin expansion over the nine-month period suggests strong operational efficiency and resilience against global headwinds.
